skip a week of tirzepatide 12-week plan 🥦💊 On a GLP-1? You

It is a once-weekly dual GIP/GLP-1 receptor agonist with impressive clinical results, achieving weight reductions of 16.0% to 22.5% in the SURMOUNT-1 Phase 3 trials

NO Pharmaceutical Grade White or almost white powder 1) Obesity Treatment: In the Phase II clinical trial, patients in the highest dose group (12 mg) lost an average of 24.2% weight after 48 weeks, and some patients lost more than 30%

5 This wide distribution of incretin hormone receptors may indicate important whole-body functions of these compounds

Molecular modification of peptide drug can be performed to improve their stability, extend their in vivo half-life and make them long-acting